XJPX4894
Market cap228mUSD
Jan 14, Last price
4,590.00JPY
1D
-3.97%
1Q
-43.75%
IPO
184.74%
Name
Cuorips Inc
Chart & Performance
P/E
—
P/S
1,560.17
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
23m
-39.65%
Net income
-632m
L+39.84%
CFO
-451m
L+12.31%
Profile
Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of iPS cell-derived cardiomyocyte sheets. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | |
| Income | ||||
Revenues | 23,102 -39.65% | 38,278 175.12% | 13,913 6,224.09% | |
Cost of revenue | 13,471 | 656,713 | 499,982 | |
Unusual Expense (Income) | ||||
NOPBT | 9,631 | (618,435) | (486,069) | |
NOPBT Margin | 41.69% | |||
Operating Taxes | 2,230 | 2,198 | 2,197 | |
Tax Rate | 23.15% | |||
NOPAT | 7,401 | (620,633) | (488,266) | |
Net income | (632,183) 39.84% | (452,077) 20.45% | (375,337) 21.93% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 3,142,069 | 10,694 | 48,541 | |
BB yield | -11.53% | |||
| Debt | ||||
Debt current | ||||
Long-term debt | ||||
Deferred revenue | ||||
Other long-term liabilities | 28,437 | 28,367 | 28,294 | |
Net debt | (5,582,270) | (2,983,896) | (3,384,782) | |
| Cash flow | ||||
Cash from operating activities | (451,060) | (401,612) | (220,762) | |
CAPEX | (35,948) | (10,566) | (28,691) | |
Cash from investing activities | (34,998) | (8,968) | (28,444) | |
Cash from financing activities | 3,125,418 | 10,694 | 48,541 | |
FCF | 55,547 | (548,931) | (420,602) | |
| Balance | ||||
Cash | 5,582,270 | 2,941,896 | 3,341,782 | |
Long term investments | 42,000 | 43,000 | ||
Excess cash | 5,581,115 | 2,981,982 | 3,384,086 | |
Stockholders' equity | (497,912) | (1,444,955) | (994,877) | |
Invested Capital | 6,510,128 | 4,924,094 | 4,915,867 | |
ROIC | 0.13% | |||
ROCE | 0.16% | |||
| EV | ||||
Common stock shares outstanding | 7,362 | 7,542 | 7,542 | |
Price | 3,700.00 | |||
Market cap | 27,240,299 | |||
EV | 21,659,529 | |||
EBITDA | 79,733 | (539,779) | (393,330) | |
EV/EBITDA | 271.65 | |||
Interest | 19,474 | |||
Interest/NOPBT | 202.20% | |||